123 / 140
Principios generales de tratamiento particularizado de los sarcomas de partes blandas según histología
>
123
BIBLIOGRAFÍA
Introducción
1. Scurr M. Histology-Driven Chemotherapy in Soft Tissue Sarcomas. Curr Treat Options Oncol
2011;12:32-45.
Liposarcoma
2. Manji GA, Schwartz GK. Managing Liposarcomas: Cutting Through the Fat. J Oncol Pract 2016;12(3):221-7.
3. Kollár A, Benson C. Current management options for liposarcoma and challenges for the future. Expert Rev
Anticancer Ther 2014;14(3):297-306.
4. Jones RL, Fisher C, Al-Muderis O, et al. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur
J Cancer 2005;41(18):2853-60.
5. Patel SR, Burgess M, Plager C, et al. Myxoid liposarcoma. Experience with chemotherapy. Cancer 1994;74:1265-9.
6. Sleijfer S, Ouali M, van Glabbeke M, et al. Prognostic and predictive factors for outcome to first-line ifosfa-
mide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retro-
spective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft
Tissue and Bone Sarcoma Group (EORTC-STBSG). Eur J Cancer 2010;46:72-83.
7. Katz D, Piyaporn B, Choi H, et al. Efficacy of first-line doxorubicin and ifosfamide in myxoid liposarcoma.
Clin Sarcoma Res 2012;2:2.
8. Sanfilippo R, Bertulli R, Marrari A, et al. High-dose continuous-infusion ifosfamide in advanced well-differ-
entiated/dedifferentiated liposarcoma. Clin Sarcoma Res 2014;22;4(1):16.
9. García-Carbonero R, Supko JG, Manola J, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in
patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 2004;22(8):1480-90.
10. García-Carbonero R, Supko JG, Maki RG, et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive pa-
tients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol
2005;23(24):5484-92.
11. Le Cesne A, Blay JY, Judson I, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European
Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial.
J Clin Oncol 2005;23(3):576-84.
12. Demetri GD, von Mehren M, Jones RL, et al. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic
Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Ran-
domized Multicenter Clinical Trial. J Clin Oncol 2016;34:786-93.
13. Samuels BL, Chawla S, Patel S, et al. Clinical outcomes and safety with trabectedin therapy in patients with
advanced soft tissue sarcomas following failure of prior chemotherapy: results of a worldwide expanded access
program study. Ann Oncol 2013;24:1703-9.
14. Le Cesne A, Cresta S, Maki R, et al. A retrospective analysis of antitumour activity with trabectedin in trans-
location-related sarcomas. Eur J Cancer 2012;48:3036-44.
15. Grosso F, Jones RL, Demetri GD, et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated
myxoid liposarcomas: a retrospective study. Lancet Oncol 2007;8(7):595-602.
16. Blay JY, Leahy MG, Nguyen BB, et al. Randomised phase III trial of trabectedin versus doxorubicin-based
chemotherapy as first-line therapy in translocation-related sarcomas. Eur J Cancer 2014;50(6):1137-47.
17. Schöffski P, Chawla S, MakI RG, et al. Eribulin versus dacarbazine in previously treated patients with advanced
liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet 2016;387:1629-37.
18. Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with
gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research
through collaboration study 002. J Clin Oncol 2007;25(19):2755-63.
19. Italiano A, Garbay D, Cioffi A, et al. Advanced pleomorphic liposarcomas: clinical outcome and impact of
chemotherapy. Ann Oncol 2012;23(8):2205-6.
20. Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with
relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European Organisation for Re-
search and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC Study 62043). J Clin Oncol
2009;27:3126-32.